Trials / Completed
CompletedNCT05455879
Impact of Antenatal Corticosteroid Therapy on Postnatal Surfactant Use in Preterm Infants
Impact of the Number of Doses of Antenatal Corticosteroid Therapy on the Number of Doses of Surfactants Postnatal in Preterm Infants
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 145 (actual)
- Sponsor
- Hôpital NOVO · Academic / Other
- Sex
- All
- Age
- 37 Weeks
- Healthy volunteers
- Not accepted
Summary
No study has shown that two doses of corticosteroids are more effective than a single dose in lung maturation and prevention of hyaline membrane disease (HMD) The aim of this study is to assess the impact of the number of doses on the severity of HMD.
Detailed description
Respiratory distress syndrome (RDS), formerly known as hyaline membrane disease, is a common problem in preterm infants. This disorder is caused primarily by deficiency of pulmonary surfactant in an immature lung. RDS is a major cause of morbidity and mortality in preterm infants. Surfactant therapy has been shown to significantly reduce neonatal and infant mortality. Corticosteroids are given antenatal, and then surfactant is given, along with corticosteroids, postnatal. A single course of corticosteroids is recommended for pregnant women between 24 weeks and 34 weeks of gestation who are at risk of preterm delivery within 7 days, including those with ruptured membranes and multiple pregnancies. Betamethasone is recommended as the steroid of choice, to be administered in two doses of 12 mg given intramuscularly 24 hours apart.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Impact of antenatal corticosteroid therapy on surfactants use postnatal | Intervention Description: Retrospective study on preterm infants to evaluate the impact of antenatal corticosteroid therapy on surfactants use postnatal |
Timeline
- Start date
- 2022-06-20
- Primary completion
- 2022-07-05
- Completion
- 2022-07-05
- First posted
- 2022-07-13
- Last updated
- 2024-09-19
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05455879. Inclusion in this directory is not an endorsement.